Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes

NCT04893148 · Unknown status

Last updated 2026-05-28

This clinical trial compared the effects of a combination medication (iGlarLixi) to insulin glargine plus dulaglutide in adults with type 2 diabetes to see how well they lower blood sugar levels.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 40 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2020-05 · est. completion 2022-12

Where 1 site · South Korea

What this study is testing ClinicalTrials.gov NCT04893148 ↗

Description as written by the study sponsor.

The investigators aimed to compare efficacy and safety of IGlarLixi and insulin glargine plus dulaglutide as intensification from basal insulin with metformin, in the absence of head-to-head trials.

Treatments tested

IGlarLixi Drug

Changing to iGlarLixi from insulin glargine
Dulaglutide also known as Insulin Glargine Drug

Add dulaglutide to insulin glargine

Main thing measured	Changes in glycated hemoglobin (HbA1c)
Sponsor	Chungbuk National University Hospital
Conditions studied	Type 2 Diabetes Mellitus, Glucose, High Blood
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04893148 ↗